Literature DB >> 30478977

Outcomes of observation without empiric intravenous antibiotics in febrile, nonneutropenic pediatric oncology patients.

Natalie Wu1, William Muller2, Elaine Morgan3.   

Abstract

There are no consensus guidelines for management of pediatric oncology patients presenting with fever and nonneutropenia, with limited research into the outcomes of withholding empiric i.v. antibiotics. We conducted a prospective cohort study assessing the safety and efficacy of observing well-appearing patients presenting with fever and nonneutropenia (absolute neutrophil count ≥ 500 cells/mm3 ). Of 238 episodes, 82.7% patients were observed with no infectious complications and low overall incidence of bacteremia (3.4%). There were no significant differences in individual clinical variables. We propose that observation alone in some well-appearing febrile pediatric oncology patients is safe and limits the use of unnecessary empiric antibiotics.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  antibiotics; bacteremia; fever; nonneutropenia; observation; oncology; pediatrics

Mesh:

Year:  2018        PMID: 30478977     DOI: 10.1002/pbc.27550

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  2 in total

1.  Prospective Implementation of a Risk Prediction Model for Bloodstream Infection Safely Reduces Antibiotic Usage in Febrile Pediatric Cancer Patients Without Severe Neutropenia.

Authors:  Adam J Esbenshade; Zhiguo Zhao; Alaina Baird; Emily A Holmes; Daniel E Dulek; Ritu Banerjee; Debra L Friedman
Journal:  J Clin Oncol       Date:  2020-08-07       Impact factor: 44.544

2.  Outcomes and Disposition of Oncology Patients With Non-neutropenic Fever and Positive Blood Cultures.

Authors:  Aditya Sharma; Jitsuda Sitthi-Amorn; Patrick Gavigan; Joshua Wolf; Asya Agulnik; Alex Brenner; Ying Li; Liza-Marie Johnson
Journal:  J Pediatr Hematol Oncol       Date:  2021-03-01       Impact factor: 1.170

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.